Ivacaftor 150 mg / tezacaftor 100 mg (28) Oral Tablet / ivacaftor 150 mg (28) Oral Tablet Pack
RxNorm 1999388
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1999388 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: ivacaftor 150 mg / tezacaftor 100 mg (28) Oral Tablet / ivacaftor 150 mg (28) Oral Tablet Pack.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
PSNPrescribable
Prescribable Name (PSN):
Ivacaftor 150 mg / tezacaftor 100 mg (28) Oral Tablet / ivacaftor 150 mg (28) Oral Tablet Pack
(Atom ID: 9732654)
SYPrescribable
Synonym (SY):
Ivacaftor 150 mg / tezacaftor 100 mg (28) Oral Tablet / ivacaftor 150 mg (28) Oral Tablet Pack
(Atom ID: 9732653)
GPCKPrescribable
Generic Pack (GPCK):
{28 (ivacaftor 150 mg / tezacaftor 100 mg Oral Tablet) / 28 (ivacaftor 150 mg Oral Tablet) } Pack
(Atom ID: 9732646)
Patient Education
Ivacaftor
Ivacaftor is used to treat certain types of cystic fibrosis (an inborn disease that causes problems with breathing, digestion, and reproduction) in adults and children 4 months of age and older. Ivacaftor should be used only in people with a certain genetic make-up. Your doctor may order a blood test to help decide if this medication is right for you. Ivacaftor is in a class of medications called cystic fibrosis transmembrane conductance regulator (CFTR) potentiators. It works by improving the function of a protein in the body to decrease the build-up of thick mucus in the lungs and improving other symptoms of cystic fibrosis.
[Learn More]
Tezacaftor and Ivacaftor
The combination of tezacaftor and ivacaftor is used along with ivacaftor to treat certain types of cystic fibrosis (an inborn disease that causes problems with breathing, digestion, and reproduction) in adults and children 6 years of age and older. Tezacaftor and ivacaftor should be used only in people with a certain genetic make-up. Your doctor may order a blood test to help decide if this medication is right for you. Tezacaftor is in a class of medications called cystic fibrosis transmembrane conductance regulator (CFTR) correctors. Ivacaftor is in a class of medications called cystic fibrosis transmembrane conductance regulator (CFTR) potentiators. Both of these medications work by improving the function of a protein in the body to decrease the build-up of thick mucus in the lungs and improve other cystic fibrosis symptoms.
[Learn More]
* Please review the disclaimer below.